ENTA - エナンタ・ファ―マシュ―ティカルズ （Enanta Pharmaceuticals Inc.） エナンタ・ファ―マシュ―ティカルズENTAのチャート
ENTAの企業情報
| symbol | ENTA |
|---|---|
| 会社名 | Enanta Pharmaceuticals Inc （エナンタ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エナンタ・マシューティカル（Enanta Pharmaceuticals Inc.）は研究開発に集中するバイオテクノロジー企業である。同社は化学主導のアプローチと創薬機能を利用して、ウイルス感染および肝臓疾患の治療分野で小分子薬を作成する。同社の研究開発プログラムは非アルコール性脂肪性肝炎（NASH）/原発性胆道炎（PBC）、呼吸器合胞体ウイルス（RSV）及びB型肝炎ウイルス（HBV）を含む三つの疾患標的に集中する。同社はC型肝炎ウイルス（HCV）に対して直接作用抗ウイルス（DAA）阻害剤のクラスの一員としての新規プロテアーゼ阻害剤を発見した。これらのパリタプレビルおよびグレカププレビル（ABT-493）を含むプロテアーゼ阻害剤はAbbVie Inc. (AbbVie)と共同開発される。同社の製品候補はNASHおよびPBCに対するファルネソイドX受容体（FXR）アゴニスト製品候補及びRSVの臨床候補者であるEDP-938を含む。 エナンタ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。感染症分野での小分子薬の作成に焦点を当て、研究開発に注力する。C型肝炎ウイルス(HCV)に対する阻害剤を発見、開発している。主要製品候補は、NS3プロテア―ゼの阻害剤「ABT-450」と多剤耐性菌感染症の治療に開発している二環式の抗生物質「Bicyclolides」である。 Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2. |
| 本社所在地 | 500 Arsenal Street Watertown MA 02472 USA |
| 代表者氏名 | Bruce L.A. Carter ブルースL.A.カーター |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-607-0800 |
| 設立年月日 | 1995年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 89人 |
| url | www.enanta.com |
| nasdaq_url | https://www.nasdaq.com/symbol/enta |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 110.59200 |
| 終値（lastsale） | 77.48 |
| 時価総額（marketcap） | 1501370791.96 |
| 時価総額 | 時価総額（百万ドル） 1510.672 |
| 売上高 | 売上高（百万ドル） 215.34700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1239.288 |
| 当期純利益 | 当期純利益（百万ドル） 84.84400 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Enanta Pharmaceuticals Inc revenues increased from $26.9M to $139.4M. Net income before extraordinary items totaled $48.3M vs. loss of $18.8M. Revenues reflect Royalties increase from $26.9M to $124.4M Revenue increase from $0K to $15M. Net Income reflects Change in fair value of warrant liabilit increase from $45K (expense) to $41K (income). |
ENTAのテクニカル分析
ENTAのニュース
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023/01/03 12:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of E
ENT and Allergy Associates, LLP Board of Directors has selected Daniel Blum, MPA as its new Chief Executive Officer 2022/11/29 15:14:55 Benzinga
Tarrytown, New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) the largest ENT, Allergy, and Audiology practice in the country is pleased to announce that Daniel Blum, MPA has been appointed as its new Chief Executive Officer, effective February 27, 2023. Daniel Blum will succeed Robert Glazer who is stepping down from the CEO role after 25 years. In support of this significant transition, Robert Glazer will continue to serve as the EVP of QMMS USA, LLC in an advisory capacity through the end of 2023. Steven Gold, MD, Vice President of ENTA and Chair of the ENTA CEO Search Committee commented, "CEO succession planning has been a joint effort between senior management and the Board of Trustees. Dan''s expertise and proven leadership in healthcare matches our vision and makes him the ideal person to lead the company into the future." Dr. Gold further added, "We are confident that Dan will lead our company to new heights based on the strong foundation that Bob Glazer has provided over 25 years.
Analysts Provide An Important Insights On Enanta Pharmaceuticals Inc. (ENTA) 2022/11/26 12:30:00 Stocks Register
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) concluded the trading at $41.58 on Friday, November 25, with a fall of -7.60% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $45.00 and 5Y monthly beta was reading 0.61 with its price kept floating in the … Analysts Provide An Important Insights On Enanta Pharmaceuticals Inc. (ENTA) Read More »
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November 2022/11/22 12:00:00 Wallstreet:Online
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November: Piper Sandler 34th Annual Healthcare Conference: Fireside Chat at 2:00 p.m. ET on November 29
Enanta Pharmaceuticals PT Lowered to $54 at RBC Capital 2022/11/22 11:31:05 Investing.com
https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-lowered-to-54-at-rbc-capital-432SI-2949736
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus 2022/10/03 11:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the eld
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months 2022/09/17 12:00:00 Stocks Register
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.66% to the previous day’s close as strong demand from buyers drove the stock to $55.80. Actively observing the price movement in the last trading, the stock closed the session at $57.92, falling within a range of $54.10 … Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months Read More »
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek 2022 2022/09/07 12:30:00 Wallstreet:Online
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington,
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September 2022/09/01 11:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40
Enanta Pharmaceuticals PT Raised to $59 at Oppenheimer 2022/08/10 09:03:03 Investing.com
https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-raised-to-59-at-oppenheimer-432SI-2868790
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus 2022/10/03 11:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the eld
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months 2022/09/17 12:00:00 Stocks Register
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.66% to the previous day’s close as strong demand from buyers drove the stock to $55.80. Actively observing the price movement in the last trading, the stock closed the session at $57.92, falling within a range of $54.10 … Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months Read More »
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek 2022 2022/09/07 12:30:00 Wallstreet:Online
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington,
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September 2022/09/01 11:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40